37.10
-0.06(-0.16%)
Currency In USD
| Previous Close | 37.16 |
| Open | 37.1 |
| Day High | 37.99 |
| Day Low | 36.18 |
| 52-Week High | 39.2 |
| 52-Week Low | 8.24 |
| Volume | 1.17M |
| Average Volume | 1.42M |
| Market Cap | 2.46B |
| PE | -10.42 |
| EPS | -3.56 |
| Moving Average 50 Days | 17.9 |
| Moving Average 200 Days | 14.19 |
| Change | -0.06 |
If you invested $1000 in Mineralys Therapeutics, Inc. (MLYS) since IPO date, it would be worth $2,011.93 as of September 13, 2025 at a share price of $37.1. Whereas If you bought $1000 worth of Mineralys Therapeutics, Inc. (MLYS) shares 1 year ago, it would be worth $3,154.76 as of September 13, 2025 at a share price of $37.1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need
GlobeNewswire Inc.
Sep 05, 2025 1:00 PM GMT
~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~ ~Subgroups - including Black or African American adults, older adults, women, and par
Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Sep 04, 2025 8:01 PM GMT
RADNOR, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
GlobeNewswire Inc.
Sep 03, 2025 1:33 AM GMT
RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease